In a report issued on July 5, Mani Foroohar from SVB Securities maintained a Hold rating on RegenXBio (RGNX – Research Report), with a price target of $25.00. The company's shares closed last Wednesday at $29.94. According to TipRanks.com, Foroohar has 0 stars on 0-5 stars ranking scale with an average return of -19.1% and a 36.0% success rate. Foroohar covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Recursion Pharmaceuticals, and 4D Molecular Therapeutics. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for RegenXBio with a $47.71 average price target, a 67.5% upside from current levels.
https://www.tipranks.com/news/blurbs/svb-securities-sticks-to-their-hold-rating-for-regenxbio-rgnx?utm_source=advfn.com&utm_medium=referral
REGENXBIO (NASDAQ:RGNX)
Historical Stock Chart
From Oct 2022 to Nov 2022 Click Here for more REGENXBIO Charts.
REGENXBIO (NASDAQ:RGNX)
Historical Stock Chart
From Nov 2021 to Nov 2022 Click Here for more REGENXBIO Charts.